EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SRZN: Consonance-Hfw Acq Corp

12 Nov 25 15:59
LAST:

13.02

CHANGE:
 0.90		OPEN:
12.19		HIGH:
13.25		ASK:
0.00		VOLUME:
42.5K
CHG(%):
7.46		PREV:
12.12		LOW:
12.19		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Nov 2512.1913.2512.1912.9452.8K
11 Nov 2511.8812.4911.7312.12361.9K
10 Nov 2512.0012.2811.6611.8015.0K
07 Nov 2511.6512.5011.5112.2090.4K
06 Nov 2512.5012.5011.9112.50800
05 Nov 2512.8712.8711.3912.4236.8K
04 Nov 2513.2113.5912.5912.594.7K
03 Nov 2514.3114.3112.9813.066.2K
31 Oct 2513.7014.3813.5214.00488.9K
30 Oct 2513.4214.0013.4213.6529.2K

COMPANY PROFILE

Name:Consonance-Hfw Acq Corp
About:Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.surrozen.com
CUSIP:86889P109
CIK:0001824893
ISIN:US86889P1093
FIGI:BBG00XY94S95

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:12.335.6%
MA10:12.742.2%
MA20:13.231.6%
MA50:12.831.5%
MA100:11.3115.1%
MA200:10.6821.9%
STO9:47.29
STO14:47.29
RSI14:42.48
WPR14:-44.55
MTM14:-0.73
ROC14:-0.05 
ATR:0.74 
Week High:13.251.8%
Week Low:11.3914.3%
Month High:14.4010.6%
Month Low:11.3921.9%
Year High:18.1739.6%
Year Low:5.90120.7%
Volatility:5.35 

RECENT SPLITS

Date Ratio
14 Dec 20231-15